PDF(Pubmed)
Abstract：
UNASSIGNED: Prolonged QT intervals are extremely common in patients with cirrhosis and affect their treatment outcomes. Propranolol is often used to prevent gastroesophageal variceal hemorrhage in patients with cirrhosis; however, it is uncertain whether propranolol exerts a corrective effect on QT interval prolongation in patients with cirrhosis.
UNASSIGNED: The study aimed to investigate the therapeutic effects of propranolol on patients with cirrhosis and prolonged QT intervals.
UNASSIGNED: A retrospective cohort study approach was adopted. Patients with cirrhosis complicated by moderate-to-severe gastroesophageal varices, who were hospitalized at the Affiliated Hospital of Guangdong Medical University between 1 December 2020 and 31 November 2022, were included in the study. The patients were divided into the propranolol and control groups based on whether they had received propranolol. Upon admission, the patients underwent tests on liver and kidney functions, electrolytes, and coagulation function, as well as abdominal ultrasonography and electrocardiography. In addition to conventional treatment, the patients were followed up after the use or non-use of propranolol for treatment and subsequently underwent reexamination of the aforementioned tests.
UNASSIGNED: The propranolol group (26 patients) had an average baseline corrected QT (QTc) interval of 450.23 ± 37.18 ms, of which 14 patients (53.8%) exhibited QTc interval prolongation. Follow-up was continued for a median duration of 7.00 days after the administration of propranolol and conventional treatment. Electrocardiographic reexamination revealed a decrease in the QTc interval to 431.04 ± 34.64 ms (p = 0.014), and the number of patients with QTc interval prolongation decreased to five (19.2%; p < 0.001). After treatment with propranolol and multimodal therapy, QTc interval normalization occurred in nine patients with QTc interval prolongation, leading to a normalization rate of 64.3% (9/14). The control group (n = 58) had an average baseline QTc interval of 453.74 ± 30.03 ms, of which 33 patients (56.9%) exhibited QTc interval prolongation. After follow-up for a median duration of 7.50 days, the QTc interval was 451.79 ± 34.56 ms (p = 0.482), and the number of patients with QTc interval prolongation decreased to 30 (51.7%; p = 0.457). The QTc interval normalization rate of patients in the control group with QTc interval prolongation was merely 10.0% (3/33), which was significantly lower than that in the propranolol group (p < 0.001).
UNASSIGNED: In patients with cirrhosis complicated by QT interval prolongation, the short-term use of propranolol aids in correction of a long QT interval and provides positive therapeutic value for cirrhotic cardiomyopathy.
UNASSIGNED: The study aimed to investigate the therapeutic effects of propranolol on patients with cirrhosis and prolonged QT intervals.
UNASSIGNED: A retrospective cohort study approach was adopted. Patients with cirrhosis complicated by moderate-to-severe gastroesophageal varices, who were hospitalized at the Affiliated Hospital of Guangdong Medical University between 1 December 2020 and 31 November 2022, were included in the study. The patients were divided into the propranolol and control groups based on whether they had received propranolol. Upon admission, the patients underwent tests on liver and kidney functions, electrolytes, and coagulation function, as well as abdominal ultrasonography and electrocardiography. In addition to conventional treatment, the patients were followed up after the use or non-use of propranolol for treatment and subsequently underwent reexamination of the aforementioned tests.
UNASSIGNED: The propranolol group (26 patients) had an average baseline corrected QT (QTc) interval of 450.23 ± 37.18 ms, of which 14 patients (53.8%) exhibited QTc interval prolongation. Follow-up was continued for a median duration of 7.00 days after the administration of propranolol and conventional treatment. Electrocardiographic reexamination revealed a decrease in the QTc interval to 431.04 ± 34.64 ms (p = 0.014), and the number of patients with QTc interval prolongation decreased to five (19.2%; p < 0.001). After treatment with propranolol and multimodal therapy, QTc interval normalization occurred in nine patients with QTc interval prolongation, leading to a normalization rate of 64.3% (9/14). The control group (n = 58) had an average baseline QTc interval of 453.74 ± 30.03 ms, of which 33 patients (56.9%) exhibited QTc interval prolongation. After follow-up for a median duration of 7.50 days, the QTc interval was 451.79 ± 34.56 ms (p = 0.482), and the number of patients with QTc interval prolongation decreased to 30 (51.7%; p = 0.457). The QTc interval normalization rate of patients in the control group with QTc interval prolongation was merely 10.0% (3/33), which was significantly lower than that in the propranolol group (p < 0.001).
UNASSIGNED: In patients with cirrhosis complicated by QT interval prolongation, the short-term use of propranolol aids in correction of a long QT interval and provides positive therapeutic value for cirrhotic cardiomyopathy.
摘要：
■延长QT间期在肝硬化患者中极为常见，并影响其治疗结果。普萘洛尔通常用于预防肝硬化患者的胃食管静脉曲张破裂出血；然而，目前尚不清楚普萘洛尔对肝硬化患者QT间期延长是否有纠正作用。
■本研究旨在探讨普萘洛尔对肝硬化和QT间期延长患者的治疗效果。
■采用回顾性队列研究方法。肝硬化并发中度至重度胃食管静脉曲张的患者，2020年12月1日至2022年11月31日期间在广东医科大学附属医院住院的患者被纳入研究.根据患者是否接受过普萘洛尔，将患者分为普萘洛尔组和对照组。一被录取,病人接受了肝肾功能检查,电解质，和凝血功能，以及腹部超声和心电图。除了常规治疗外,在使用或不使用普萘洛尔治疗后对患者进行了随访,随后接受了上述检查的复查.
■普萘洛尔组（26例）的平均基线校正QT（QTc）间隔为450.23±37.18ms，其中14例(53.8%)出现QTc间期延长。在给予普萘洛尔和常规治疗后，随访的中位持续时间为7.00天。心电图复查显示QTc间期下降至431.04±34.64ms(p=0.014),QTc间期延长的患者减少到5例(19.2%;p<0.001)。普萘洛尔和多模式治疗后，9例QTc间期延长患者发生QTc间期正常化,导致正常化率为64.3%(9/14)。对照组（n=58）的平均基线QTc间隔为453.74±30.03ms，其中33例(56.9%)出现QTc间期延长。在中位持续时间为7.50天的随访后，QTc间隔为451.79±34.56ms(p=0.482)，QTc间期延长的患者减少到30例（51.7％；p=0.457）。对照组QTc间期延长患者QTc间期复常率仅为10.0%(3/33),显著低于普萘洛尔组(p<0.001)。
■在肝硬化并发QT间期延长的患者中，普萘洛尔的短期使用有助于纠正QT间期过长,并为肝硬化心肌病提供了积极的治疗价值.
■本研究旨在探讨普萘洛尔对肝硬化和QT间期延长患者的治疗效果。
■采用回顾性队列研究方法。肝硬化并发中度至重度胃食管静脉曲张的患者，2020年12月1日至2022年11月31日期间在广东医科大学附属医院住院的患者被纳入研究.根据患者是否接受过普萘洛尔，将患者分为普萘洛尔组和对照组。一被录取,病人接受了肝肾功能检查,电解质，和凝血功能，以及腹部超声和心电图。除了常规治疗外,在使用或不使用普萘洛尔治疗后对患者进行了随访,随后接受了上述检查的复查.
■普萘洛尔组（26例）的平均基线校正QT（QTc）间隔为450.23±37.18ms，其中14例(53.8%)出现QTc间期延长。在给予普萘洛尔和常规治疗后，随访的中位持续时间为7.00天。心电图复查显示QTc间期下降至431.04±34.64ms(p=0.014),QTc间期延长的患者减少到5例(19.2%;p<0.001)。普萘洛尔和多模式治疗后，9例QTc间期延长患者发生QTc间期正常化,导致正常化率为64.3%(9/14)。对照组（n=58）的平均基线QTc间隔为453.74±30.03ms，其中33例(56.9%)出现QTc间期延长。在中位持续时间为7.50天的随访后，QTc间隔为451.79±34.56ms(p=0.482)，QTc间期延长的患者减少到30例（51.7％；p=0.457）。对照组QTc间期延长患者QTc间期复常率仅为10.0%(3/33),显著低于普萘洛尔组(p<0.001)。
■在肝硬化并发QT间期延长的患者中，普萘洛尔的短期使用有助于纠正QT间期过长,并为肝硬化心肌病提供了积极的治疗价值.
